297 related articles for article (PubMed ID: 37685939)
1. Sympathetic Nervous System and Atherosclerosis.
Wang Y; Anesi J; Maier MC; Myers MA; Oqueli E; Sobey CG; Drummond GR; Denton KM
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685939
[TBL] [Abstract][Full Text] [Related]
2. Adrenergic signaling in heart failure: a balance of toxic and protective effects.
Baker AJ
Pflugers Arch; 2014 Jun; 466(6):1139-50. PubMed ID: 24623099
[TBL] [Abstract][Full Text] [Related]
3. Adrenergic receptors and cardiovascular effects of catecholamines.
Motiejunaite J; Amar L; Vidal-Petiot E
Ann Endocrinol (Paris); 2021 Jun; 82(3-4):193-197. PubMed ID: 32473788
[TBL] [Abstract][Full Text] [Related]
4. Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity?
Vrablik M; Corsini A; Tůmová E
Curr Atheroscler Rep; 2022 Mar; 24(3):161-169. PubMed ID: 35174437
[TBL] [Abstract][Full Text] [Related]
5. The human sympathetic nervous system: its relevance in hypertension and heart failure.
Parati G; Esler M
Eur Heart J; 2012 May; 33(9):1058-66. PubMed ID: 22507981
[TBL] [Abstract][Full Text] [Related]
6. Sympathetic activation and the role of beta-blockers in chronic heart failure.
Krum H
Aust N Z J Med; 1999 Jun; 29(3):418-27. PubMed ID: 10868514
[TBL] [Abstract][Full Text] [Related]
7. Beta-blockers in pulmonary arterial hypertension: Time for a second thought?
Badagliacca R; Mercurio V; Romeo E; Correale M; Masarone D; Papa S; Tocchetti CG; Agostoni P;
Vascul Pharmacol; 2022 Jun; 144():106974. PubMed ID: 35248781
[TBL] [Abstract][Full Text] [Related]
8. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications.
Triposkiadis F; Karayannis G; Giamouzis G; Skoularigis J; Louridas G; Butler J
J Am Coll Cardiol; 2009 Nov; 54(19):1747-62. PubMed ID: 19874988
[TBL] [Abstract][Full Text] [Related]
9. The role of the sympathetic nervous system in controlling bone metabolism.
Togari A; Arai M; Kondo A
Expert Opin Ther Targets; 2005 Oct; 9(5):931-40. PubMed ID: 16185149
[TBL] [Abstract][Full Text] [Related]
10. Renal sympathetic denervation for treatment of patients with heart failure: summary of the available evidence.
Nammas W; Koistinen J; Paana T; Karjalainen PP
Ann Med; 2017 Aug; 49(5):384-395. PubMed ID: 28276870
[TBL] [Abstract][Full Text] [Related]
11. Chronic bilateral renal denervation reduces cardiac hypertrophic remodelling but not β-adrenergic responsiveness in hypertensive type 1 diabetic rats.
Thaung HP; Yao Y; Bussey CT; Hughes G; Jones PP; Bahn A; Sammut IA; Lamberts RR
Exp Physiol; 2015 Jun; 100(6):628-39. PubMed ID: 25881071
[TBL] [Abstract][Full Text] [Related]
12. Role of α2-Adrenoceptors in Hypertension: Focus on Renal Sympathetic Neurotransmitter Release, Inflammation, and Sodium Homeostasis.
Hering L; Rahman M; Potthoff SA; Rump LC; Stegbauer J
Front Physiol; 2020; 11():566871. PubMed ID: 33240096
[TBL] [Abstract][Full Text] [Related]
13. Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart.
Brodde OE; Bruck H; Leineweber K; Seyfarth T
Basic Res Cardiol; 2001 Nov; 96(6):528-38. PubMed ID: 11770070
[TBL] [Abstract][Full Text] [Related]
14. Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure.
Esler M; Kaye D
J Auton Nerv Syst; 1998 Oct; 72(2-3):210-9. PubMed ID: 9851571
[TBL] [Abstract][Full Text] [Related]
15. Rationale for treatment of patients with chronic heart failure with adrenergic blockade.
Sackner-Bernstein JD; Mancini DM
JAMA; 1995 Nov; 274(18):1462-7. PubMed ID: 7474194
[TBL] [Abstract][Full Text] [Related]
16. Beta2-adrenoceptor-mediated prejunctional facilitation and postjunctional inhibition of sympathetic neuroeffector transmission in the guinea pig vas deferens.
Todorov LD; Clerkin R; Mihaylova-Todorova ST; Khoyi MA; Westfall DP
J Pharmacol Exp Ther; 2001 Aug; 298(2):623-33. PubMed ID: 11454924
[TBL] [Abstract][Full Text] [Related]
17. Sympathetic alpha(2)-adrenoceptors prevent cardiac hypertrophy and fibrosis in mice at baseline but not after chronic pressure overload.
Gilsbach R; Schneider J; Lother A; Schickinger S; Leemhuis J; Hein L
Cardiovasc Res; 2010 Jun; 86(3):432-42. PubMed ID: 20083574
[TBL] [Abstract][Full Text] [Related]
18. Prevention of ventricular fibrillation, acute myocardial infarction (myocardial necrosis), heart failure, and mortality by bretylium: is ischemic heart disease primarily adrenergic cardiovascular disease?
Bacaner M; Brietenbucher J; LaBree J
Am J Ther; 2004; 11(5):366-411. PubMed ID: 15356432
[TBL] [Abstract][Full Text] [Related]
19. Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure.
Hegde SS; Friday KF
Curr Pharm Des; 1998 Dec; 4(6):469-79. PubMed ID: 10197057
[TBL] [Abstract][Full Text] [Related]
20. Relative importance of medullary brain nuclei for the sympatho-inhibitory actions of rilmenidine in the anaesthetized rabbit.
Head GA; Burke SL
J Hypertens; 1998 Apr; 16(4):503-17. PubMed ID: 9797196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
